Speech-Language Pathologists in Two Rivers, WI Accepting Medicare

4 Speech-Language Pathologists found. Showing 1 - 4

Natalie Christensen, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5000 Memorial Dr, Two Rivers, WI 54241 Phone: 920-794-5000

Andrea Nett, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5000 Memorial Dr, Two Rivers, WI 54241 Phone: 920-794-5078

Mrs. Martha Schwobe Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5000 Memorial Dr, Two Rivers, WI 54241 Phone: 920-794-5000

Valerie Jean Shepperd, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5000 Memorial Dr, Two Rivers, WI 54241 Phone: 920-794-5176

News Archive

Improving air quality could prevent pollution-related deaths worldwide

Improving air quality - in clean and dirty places - could reduce pollution-related deaths worldwide by millions of people each year. That finding comes from a team of environmental engineering and public health researchers who developed a global model of how changes in outdoor air pollution could lead to changes in the rates of health problems such as heart attack, stroke and lung cancer.

A diet rich in milk does not increase the risk of heart disease and stroke

The research team asked a representative sample of 764 men to weigh and record every item of food and drink they consumed for seven consecutive days. Just under 90% of the sample (665) produced complete and detailed diaries.

Three new hospitals utilize PureWellness' comprehensive online employee wellness platform

PureWellness, Inc., a leading provider of online wellness solutions, announced it has signed agreements with three new hospitals; Northeast Georgia Health Systems, McCullough-Hyde Memorial Hospital, and Fletcher Allen Health Care.

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.

NCCN publishes new guidelines with NCCN Evidence Blocks for Breast, Colon, Kidney, and Rectal Cancers

The National Comprehensive Cancer Network has published the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with NCCN Evidence Blocks™ for Breast, Colon, Kidney, and Rectal Cancers.

Read more Medical News

› Verified 8 days ago